BOLT Investors Have the Opportunity to Lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Provided By PR Newswire
Last update: Aug 22, 2024
LOS ANGELES, Aug. 22, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Bolt Biotherapeutics, Inc. ("Bolt" or "the Company") (NASDAQ: BOLT) for violations of ยงยง10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Read more at prnewswire.com0.298
-0.03 (-7.97%)
Find more stocks in the Stock Screener
BOLT Latest News and Analysis
a day ago - ChartmillStay updated with the stocks that are on the move in today's after-hours session.Discover the top movers in Wednesday's after-hours session and stay informed about the post-market dynamics.
